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Background: Chest-X-ray has several limitations in detecting the extent of pulmonary disease in sarcoidosis. It
might not reflect the degree of pulmonary involvement in patients with sarcoidosis when compared to computed
tomography of the thorax. We aimed to investigate the HRCT findings of pulmonary sarcoidosis and to find out the
existence of possible relations between HRCT findings and PFTs. In addition, we aimed to investigate the
accordance between HRCT findings and conventional chest-X-ray staging of pulmonary sarcoidosis.
Method: 45 patients with sarcoidosis with a mean age 29.7+/− 8.4 years were evaluated. Six of them were female
and 39 were male. The type, distribution and extent of the parameters on HRCT/CTs were evaluated and scored.
Chest-X-rays were evaluated for the stage of pulmonary sarcoidosis. Correlations were investigated between HRCT/
CT parameter scores, Chest X-Ray stages and pulmonary function parameters.
Results: Nodule, micronodule, ground glass opacity and consolidation were the most common HRCT findings.
There were significant correlations between pulmonary function parameters, HRCT pattern scores, and chest-X-ray
stages. A significant correlation between chest-x-ray score and total HRCT score was found.
Conclusions: Pulmonary sarcoidosis patients might have various pulmonary parenchymal changes on HRCT. Thorax
HRCT was superior to chest-X-ray in detecting pulmonary parenchymal abnormalities. The degree of pulmonary
involvement might be closely related to the loss of pulmonary function measured by PFTs. Chest-X-ray is
considered to have a role in the evaluation of pulmonary sarcoidosis.Background
Sarcoidosis is a systemic granulomatous disease of un-
known etiology mainly involving the mediastinum and the
lungs. The diagnosis is usually based on typical radiological
findings as bilateral symmetric hilar lymphadenopathies,
demonstration of non-caseating granulomas along with the
exclusion of other known granulomatous diseases [1-4].
More than one organ or system involvement at the time of
diagnosis is a usual feature of the disease. Even though it is
a chronic disorder, remissions during the course of the
disease are common especially in the lower radiologic
stages of the disease [1-5]. Mainly for this reason, in clinical
practice the treatment with steroids is indicated for patients
with severe pulmonary disease. In addition, steroid treat-
ment might also change the natural course of the disease
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reproduction in any medium, provided the orsarcoidosis are not certain, and in some patients with
sarcoidosis making the decision of steroid treatment might
be troublesome. This is usually the case for pulmonary
sarcoidosis patients having borderline pulmonary function
test (PFT) results since a treatment decision for pulmonary
sarcoidosis mainly based on the degree of impairment in
pulmonary function tests and/or the radiological extent of
pulmonary disease [1,7]. Chest-X-ray has several limitations
in detecting the extent of pulmonary disease in sarcoidosis.
It might not reflect the degree of pulmonary involvement
in patients with sarcoidosis when compared to computed
tomography of the thorax [5,7-9]. PFTs are generally used
to determine the degree of impairment in pulmonary func-
tion in many diseases. However, there are not enough data
about whether PFTs reflect the degree of pulmonary paren-
chymal involvement in pulmonary sarcoidosis. Mainly for
these reasons, we aimed to investigate the HRCT findings
of pulmonary sarcoidosis and to find out the existence of
possible relationships between HRCT findings and PFTs. In
addition, we aimed to investigate the accordance between. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pulmonary sarcoidosis.
Method
Medical records of the patients with pulmonary sarcoidosis
between 2005 and 2012 were screened retrospectively.
Patients having a diagnosis of sarcoidosis were included
into the study. Except for 4 of them, all the PFTs and CT
scans (CTs) were performed within one month. For 4
patients the aforementioned procedures were performed
within 2 months. Patients having no retrieved PFTs or
thorax CTs were excluded from the study. As a result, 45
patients with sarcoidosis, with a mean age 29.7 ± 8.4 years,
were evaluated. There were 6 females (mean age:41.8 ±
12.6) and 39 males (mean age:27.9 ± 5.9).
The scoring and the evaluation of CTs and chest X rays
were performed by two radiologists. If there was any dis-
agreement between them, their final consensus score was
recorded. HRCTs of 40 patients and thorax CTs of
5 patients were evaluated. CTs were performed at 5 mm
section interval and HRCTs were performed 10 mm section
interval (120 kV, 175 mA), [1 mm slice thickness, 1.5 s
scanning time] using the GE Medical System HiSpeed CT/i
(Milwaukee, USA) or the 16-slice MDCT (Philips, MX
8000 IDT 16, Best, The Netherlands) machines. The follow-
ing and previously defined [10] HRCT patterns were evalu-
ated: nodule (N), micronodule (MN), consolidation (C),
ground glass opacity (GGO) (Figure 1), parenchymal band
(PB), centrilobular emphysema, panacinar emphysema,Figure 1 Some HRCT patterns (A: Ground glass opacity, B: Micronoduparaseptal emphysema, bronchiectasis, interlobular septal
thickening (ILST), intralobular septal thickening (intraLST)
and subpleural interstitial thickening (SPIT). The distribu-
tion and extent of the parameters on HRCTs or on thorax
CTs were determined as previously defined [11] and as
following: parenchymal areas above the main carina were
upper zones, areas below lower pulmonary veins were
lower zones and areas between two zones were the middle
zones of each lung. The degree of involvement was scored
as following : no involvement 0 point, involvement up to
25% of a previously defined lung zone 1 point, involvement
between 25% and 50% of a lung zone 2 points, involvement
between 50% and 75% of a lung zone 3 points and involve-
ment more than 75% of a lung zone 4 points. Thus for
every single parameter, a patient might have 24 points. The
sum of the scores of every single parameter for each patient
was defined as total HRCT score.
We could retrieve chest-X-rays of 42 patients. Chest-
X-rays of the patients were also evaluated for the stage
of pulmonary sarcoidosis [1,4,7]. Twenty two patients
were classified as radiologic stage 1, 14 patients as stage
2, 4 patients as stage 3 and 2 patients as stage 4. Patients
were compared for total HRCT scores according to their
radiological stages by using One-way ANOVA test.
The localizations of lymph nodes were determined and
documented as hilar, mediastinal, paratracheal, para-
aortic and subaortic. In one patient the localization of
lymph nodes was not determined because the mediasti-
num was not visualized due to type of the radiologicle, C: Nodule, D: Consolidation).
Table 1 The amount of HRCT patterns
N Minimum Maximum Mean SD
MN 41 1 21 7,3 4,5
N 37 1 10 4,5 2,3
C 21 1 10 4,1 2,8
GGO 36 1 12 4,8 2,8
BL 16 1 9 3,5 2,2
CLE 1 1 1 1 .
PANE 5 2 3 2,2 0,4
PSE 3 1 5 2,3 2,3
ILST 7 1 4 2,7 1,1
IntraLST 4 1 4 2 1,4
SPIT 23 1 2 1,8 0,3
PB 24 1 11 4,5 3,1
Cavity 1 1 1 1 .
BVB 27 1 4 1,9 0,6
Air cyst 1 1 1 1 .
BL, Bronchial lesions; BVB, Bronchovascular bundle; C, Consolidation; CLE,
Centrilobular emphysema; GGO, Ground glass opacity; ILST, Interlobular septal
thickening; IntraLST, Intralobularseptal thickening; MN, Micronodule; N, Nodule;
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also evaluated and scored as mild, moderate and severe
for each patient [7].
Spirometric parameters and diffusion parameters were
measured by using either Vmax encore system (VIASYS
Healthcare) or Cosmed Quark PFT 1 system. In 29 patients
both spirometric measurements and diffusion measure-
ments were done by using Vmax encore system. In five
patients spirometric measurements were done by using
Quark PFT 1 and diffusion measurements were done by
using Wmax encore system. In 11 patients only spirometric
measurements were done by using Quark PFT 1 system.
“ERS 93” was used for predicted values in Quark PFT 1 sys-
tem. “ERS 1993 Update + Zapletal” was used for predicted
values in Vmax encore system.
Correlations were investigated between the results of
pulmonary function measurements and the score of every
single HRCT/CT parameter, the total HRCT scores and
the chest-X-ray scores. A correlation was investigated
between total HRCT scores and chest-X-ray scores. Pear-
son correlation test for parametric variables and Spearman
correlation test for non parametric variables were used.PANE, Panacinar emphysema; PB, Parenchymal band; PSE, Paraseptal
emphysema; SPIT, Subpleural interstitial thickening; SD, Standard Deviation.
Table 2 Spirometry and lung diffusion values of the
patients
n Mean (SD) Minimum Maximum
FVC (L) 45 4.56 (1.22) 1.65 6.61
FVC (%) 45 93.9 (15.8) 56.0 120.0
FEV1(L) 45 3.63 (1.04) 1.11 5.43
FEV1 (%) 45 88.6 (17.6) 45.0 117.0
FEV1/FVC 45 79.9 (9.1) 41.0 94.0
FEF25-75 (L) 44 3.53 (1.39) 0.75 6.34
FEF25-75 (%) 44 74.1 (25.0) 16.0 124.0
DLCO (mL/mmHg/min) 34 29.7 (7.7) 11.70 44.50
DLCO (%) 34 88.0 (17.1) 52.0 136.0
DLCO/VA 34 5.0 (0.8) 3.78 6.84
DLCO/VA (%) 34 99.3 (14.7) 75.0 138.0
VA 34 6.0 (1.4) 2.99 8.37
VA (%) 34 88.8 (13.9) 52.0 117.0
DLCO-Hb* 34 29.8 (8.4) 11.1 43.8
SD, Standard Deviation.
*DLCO corrected for Hb value.Results
HRCT showed a wide spectrum of patterns: in some
patients the pulmonary parenchyma was nearly clear,
while in others almost all kinds of HRCT patterns were
found. The amount of HRCT patterns are listed in Table 1.
N, MN, GGO and consolidation were the most common
HRCT findings. Spirometry and lung diffusion results are
shown in Table 2. There were significant correlations be-
tween pulmonary function parameters and total HRCT
scores, and HRCT pattern scores (Table 3). In Figure 2
correlations between total HRCT scores and spirometric
values are displayed with scatter plot graphics.
At Chest X-ray evaluation 22 patients had radiologic
stage 1, 14 patients stage 2, 4 patients stage 3 and 2
patients stage 4. Comparing the HRCT scores among the
different chest-X-ray stages, the patients at radiological
stage I had significantly lesser mean total HRCT score
than those in stages II, III and IV, respectively (Table 4). In
addition, there were significant correlations between
chest-X-ray stage and pulmonary function tests (Table 5).
A significant correlation between chest-X-ray stage and
total HRCT score was also found (rho:0.72, p = 0.0001).
Among the 44 patients whose lymph nodes were eva-
luated, there was only one patient with no lymph node
involvement on thorax CTs. All other patients had several
amounts of lymphadenopathies on their CTs. The degree
of lymph node involvement was mild in 12 patients, mod-
erate in 18 , and severe in 13.
Twenty two patients (50%) had lymph nodes enlargement
in all, previously defined stations, that is the paratracheal,subcarinal, precarinal, right hilar, left hilar, paraaortic and
subaortic areas. The frequency of lymph node involvement
in each station was as follows : paratracheal in 43 patients
(98%), subcarinal in 42 (95%), right hilar in 41 (93%), left
hilar in 40 (91%), para-aortic in 38 (86%), precarinal in 31
(70%), and subaortic in 29 (66%) patients. Thus, paractra-
cheal lymph nodes were the most frequently involved
(Table 6).
Table 3 Correlations between pulmonary function parameters, total HRCT scores and HRCT pattern scores
FVC (n = 45) FVC (%) (n = 45) FEV1 (n = 45) FEV1 (%) (n = 45) FEV1/FVC (n = 45) FEF25-75 (n = 44) FEF25-75 (%) (n = 44)
r p r p r p r p r P r p r p
Total HRCT score −0.55 0.0001 −0.49 0.001 −0.66 0.0001 −0.64 0.0001 −0.33 0.03 −0.55 0.0001 −0.53 0.0002
MN score −0.34 0.02 −0.35 0.02 −0.38 0.01 −0.39 0.008 −0.04 0.79 −0.29 0.05 −0.29 0.06
N score −0.60 0.0001 −0.55 0.0001 −0.63 0.0001 −0.60 0.0001 −0.20 0.19 −0.48 0.001 −0.45 0.002
C score −0.35 0.02 −0.35 0.02 −0.50 0.0001 −0.56 0.0001 −0.43 0.004 −0.44 0.003 −0.47 0.001
GGO score −0.38 0.009 −0.29 0.06 −0.43 0.003 −0.36 0.02 −0.17 0.26 −0.34 0.02 −0.32 0.04
BL score −0.46 0.001 −0.35 0.02 −0.58 0.0001 −0.51 0.0001 −0.37 0.01 −0.49 0.001 −0.44 0.003
SPIT score −0.22 0.14 −0.20 0.19 −0.24 0.11 −0.24 0.11 −0.14 0.37 −0.22 0.15 −0.19 0.22
PB score −0.48 0.001 −0.40 0.006 −0.61 0.0001 −0.58 0.0001 −0.39 0.008 −0.53 0.0001 −0.50 0.001
BVB score −0.13 0.38 −0.16 0.30 −0.21 0.16 −0.25 0.09 −0.11 0.46 −0.20 0.21 −0.23 0.14
DLCO (n = 34) DLCO (%) (n = 34) DLCO/VA (n = 34) DLCO/VA% (n = 34) VA (n = 34) VA% (n = 34) DLCO-Hb* (n = 34)
r p r P r p r p r p r p r p
Total HRCT score −0.40 0.018 −0.33 0.06 0.10 0.59 0.13 0.45 −0.51 0.002 −0.53 0.001 −0.41 0.015
MN score −0.08 0.66 −0.06 0.74 0.17 0.34 0.17 0.34 −0.18 0.30 −0.23 0.20 −0.09 0.62
N score −0.41 0.016 −0.29 0.10 0.21 0.23 0.22 0.21 −0.58 0.0004 −0.54 0.001 −0.41 0.016
C score −0.25 0.15 −0.21 0.24 0.08 0.64 0.10 0.56 −0.32 0.066 −0.32 0.06 −0.25 0.15
GGO score −0.44 0.008 −0.38 0.03 −0.02 0.92 −0.01 0.95 −0.49 0.003 −0.46 0.006 −0.44 0.009
BL score −0.46 0.006 −0.40 0.02 −0.05 0.78 −0.01 0.95 −0.50 0.002 −0.52 0.002 −0.47 0.005
SPIT score −0.04 0.81 −0.08 0.66 0.02 0.92 0.02 0.92 −0.09 0.61 −0.15 0.40 −0.03 0.85
PB score −0.44 0.009 −0.38 0.03 0.06 0.75 0.10 0.57 −0.54 0.001 −0.57 0.0005 −0.47 0.005
BVB score 0.14 0.44 0.16 0.38 0.24 0.17 0.17 0.34 −0.1 0.57 −0.1 0.58 0.12 0.51
BL, Bronchial lesions; BVB, Bronchovascular bundle; C, Consolidation; GGO, Ground glass opacity; MN, Micronodule; N, Nodule; SPIT, Subpleural interstitial thickening; PB, Parenchymal band.





















Figure 2 Correlations between total HRCT scores and spirometric values displayed with scatter plot graphics.
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In this study we have shown that MNs pattern is the most
common among the wide range of abnormalities found
in HRCT of patients with pulmonary sarcoidosis. This
should not be surprising, because theoretically MNs can
be considered the fundamental finding of parenchymal
involvement in pulmonary sarcoidosis. In fact, by defi-
nition, sarcoidosis is a systemic granulomatous disease
mainly involving lymphatic system, such as the formation
and presence of MNs are to be expected [1,5,8,12]. Sup-
porting our hypothesis, studies have shown that parenchy-
mal biopsies obtained from MNs in sarcoidosis patients
revealed non-caseating granulomas. It is also well known
that the shape of granulomas is usually round and their
dimensions may vary from micrometers to millimeters
[2,8,13,14]. Also, due to systemic nature of the disease,
every single organ or system might be involved to someTable 4 Mean total HRCT scores for Chest-X-ray stages




2 4 48.5extent in sarcoidosis, even though we could not visualize
all these possible localizations of the disease by conven-
tional imaging/screening methods, because they can be
too small in some organs or systems to be visualized with
these techniques [3,15]. From this point of view, we may
speculate that easy and repeatable lung imaging by con-
ventional methods might have led us to consider the lungs
to be the most involved organs in sarcoidosis even though
this might not be true. Furthermore, when compared to
conventional methods, HRCT is more sophisticated to
visualize lung parenchyma in a detailed manner; and
HRCT has the capability to reveal very subtle or minimal
involvements/changes in the lung parenchyma [16,17]. As
a result, the demonstration of MNs might be considered
as a good example for this condition in sarcoidosis
patients. In many studies it was shown that the distribu-
tion of MNs was perilymphatic in HRCTs of patients with
pulmonary sarcoidosis [3,5,8,14-16]. That is : MNs are
mostly located in sub pleural regions, in broncho vascular
bundles and sometimes in interlobular septae [3,8,16] in-
dicating that the disease is related to lymphatic system
from another point of view. This kind of distribution of
MNs can also be seen in patients with lymphangitis carci-
nomatosa and amiloidosis [10,18]. The distribution of
MNs was also perilymphatic in our study patients. We can




FVC (n = 42) −0.60 0.0001
FVC (%) (n = 42) −0.54 0.0003
FEV1 (n = 42) −0.53 0.0003
FEV1 (%) (n = 42) −0.54 0.0002
FEV1/FVC (n = 42) 0.14 0.37
FEF25-75 (n = 41) −0.28 0.076
FEF25-75 (%) (n = 41) −0.25 0.11
DLCO (n = 31) −0.31 0.087
DLCO (%) (n = 31) −0.24 0.20
DLCO/VA (n = 31) 0.23 0.21
DLCO/VA (%) (n = 31) 0.15 0.41
VA (n = 31) −0.51 0.003
VA% (n = 31) −0.41 0.021
DLCO-Hb (n = 31) −0.26 0.16
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some degree, the extent of the sarcoidosis involvement in
the lungs. Compatible with this hypothesis, we have
shown that there were significant correlations between
spirometric values; FVC, FVC%, FEV1, FEV1%, FEF25-75
and FEF25-75% and MN scores. This finding might suggest
that the more is the amount of the MNs , the less the
spirometric values are. This finding indirectly suggests
that the loss of pulmonary function in pulmonary sarcoid-
osis is related to the amount of MNs in HRCT since it is
very well known that these spirometric values globally
might reflect the degree of the impairment in lung
function [19].
In addition, perilymphatic distribution of MNs might
also contribute to their limiting effects on lung function
since anatomically the hypothetical skeleton of the lungs
could be regarded as involved by this kind of distribution.Table 6 Involvement of lymph node stations
Involvement of lymph node stations N = 44 %
Paratracheal 43 98
Subcarinal 42 95
Right hilar 41 93




All regions 22 50
No involvement 1 2Nodules were defined as rounded opacities more than
3 mm and less than 10 mm in diameter. They can form
mainly in two ways :growth of a MN with time , or con-
fluence of several MNs [5,10]. From this point of view
we can propose that nodules reflect a more advanced
disease stage than MNs. However, whatever the way they
are formed, the nodules are supposed to have the similar
appearance as MNs on HRCT, apart from their dimen-
sions. The distribution of nodules was usually peri-
lymphatic and similar to MNs in our patients.
Twenty one patients had some degree of consolidation
on their HRCTs. Consolidation can form as an acute
disease or as a result of confluence of nodules; fibrotic
masses can also be considered as consolidation [5,8,10,17].
Consolidation is not infrequent but a confusing finding in
differential diagnosis of the sarcoidosis since it mimics
many diseases such as pneumonia and irregular malignant
masses. Sometimes, consolidated areas in the lung paren-
chyma look like scattered stars resembling a galaxy, and
for this reason such pattern is called “galaxy sign” [5,13].
This finding might also mimic metastatic lung cancer
[17,20]. Furthermore, pulmonary sarcoidosis presenting
predominantly with consolidation is also called alveolar
sarcoidosis [3,5,13,16,17]. Consolidation is a lesion occu-
pying space in the lungs, thus the presence of consolida-
tion might be expected to inversely associate with the
results of lung function tests. Contributing to this hypoth-
esis significant and negative correlations were found in the
present study between consolidation scores and spirometric
values : FVC, FVC%, FEV1, FEV1%, FEF25-75, FEF25-75%.
GGO can form mainly as a result of certain diseases or
conditions characterized by accumulation of fluid, blood,
inflammatory or malignant cells in alveoli, such as alveolar
hemorrhage, alveolar proteinosis, viral pneumonia, intersti-
tial lung diseases etc. [10]. However, in sarcoidosis the con-
fluence of granulomas was reckoned to be responsible for
GGO appearance on HRCT rather than a true alveolitis
[5,13,16]. It sometimes surrounds consolidation which is
called as "halo sign" and when its surrounded by consolida-
tion it is called as "reversed halo sign". These findings could
also be seen in a variety of disorders such as fungal infec-
tions and organizing pneumonia [21-23]. GGO might also
be considered as a light or less dense form of consolidation.
GGO was found in most our patients. Since alveoli are the
main site involved in GGO appearance and they are
the main site of gas exchange, we can hypothesize that the
presence of GGO might be inversely related to gas
exchange parameters. Compatible with our hypothesis, a
significant and negative correlation between GGO scores,
DLCO and DLCO% values were found in the present study.
In addition, significant and negative correlations were
found between GGO scores and spirometric values.
When combining all our findings, we might say that the
correlations between MN and N scores and reduction in
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increase in the number of micronodules and/or nodules
may determine a reduction in lung volumes.
Total HRCT score can be supposed to reflect the degree
of pulmonary parenchymal involvement more than any
single parenchymal lesion in pulmonary sarcoidosis
patients since it includes almost all the parenchymal
lesions seen on HRCT. Compatible with this hypothesis
significant and negative correlations were found between
total HRCT scores and PFT parameters indicating reduced
lung volumes. This finding suggests that rather than any
single lesion such as MN or N, a combination of all lesions
seen in HRCT can be strongly related to the reductions in
lung volumes in sarcoidosis patients.
In this study we have also shown that staging of the
disease with respect to conventional chest-x-ray did not
reflect the status of actual parenchymal involvement in
patients with sarcoidosis. In fact, although there were 22
patients with sarcoidosis at radiologic stage 1 according
to chest-X-rays, nevertheless only few patients had
almost clear parenchymal HRCT images. The low sensi-
tivity of chest-x-ray in detecting subtle parenchymal
changes in lung parenchyma likely is the main reason
for this finding. Before the introduction of HRCT for the
imaging of lungs, chest-X-ray had been used for an aid
to the evaluation, staging and monitoring of the disease
along with spirometric and diffusion tests [3,7,16]. How-
ever the interpretation of chest-X-ray might be limited
by many factors such as weight, position and the degree
of inspiration of the patient, the dose of the beam etc. In
addition, the superimposition of many intrathoracic
structures is another limiting factor. From this point of
view, our finding should not be surprising but an
expected one. Several new studies indicate the low value
of chest-x-ray in clinical decision making in patients
with parenchymal lung diseases [3,7,16,17,24]. On the
other hand, clinical usefulness of chest-X-ray should not
be discarded in pulmonary sarcoidosis since patients
with radiological stage I disease had significantly less
mean total HRCT score than patients with other chest
x-ray stages. Furthermore, we have found significant cor-
relations between radiologic stages of the disease and
total HRCT scores. These findings might be interpreted
as following : even though chest-X-ray does not neces-
sarily reflect the degree of actual involvement in pul-
monary parenchyma, it has a considerable value for the
estimation of the existence of pulmonary involvement.
Supporting the aforementioned interpretation, we have
also found significant correlations between chest-X-ray
scores and pulmonary function test parameters. As a
whole, our results suggest that chest-X-ray along with
pulmonary function tests might be used to determine
the functional status of pulmonary sarcoidosis patients.
However these findings should not induce to considerthat chest-X-ray is comparable to computed tomography
or that it can be used to monitor the disease.
Compatible with the current literature [3,5,8,17], we
have also shown that lymph nodes in paratracheal area
were the most involved lymph nodes, preceding subcar-
inal, and other lymph node stations. Except one patient
all patients had lymph nodes in both hilar regions. There
was a strong correlation between chest-X-ray hilar score
values and CT LAP score values suggesting that chest-
X-ray might be used to estimate the amount of lympha-
denopathies without using computed tomography.
Although the retrospective nature of our study might
be possible limitation, we believe it is informative since
we tried to document the findings obtainable in patients
with pulmonary sarcoidosis by means of pulmonary
function tests and CT scans and the possible relation-
ships between them, that we also interpreted in the light
of the current literature.
Conclusions
In conclusion, we have shown that pulmonary sarcoidosis
patients may have various pulmonary parenchymal
changes, also seen in other interstitial lung diseases. Even
though it is an expected finding and its clinical significance
is debatable, we have also shown that thorax HRCT was
significantly superior to chest-X-ray in detecting pulmonary
parenchymal abnormalities. Nevertheless, our results also
suggest that chest-X-ray along with pulmonary function
tests might be used to determine the functional status of
patients with pulmonary sarcoidosis. We have also shown
that the degree of pulmonary involvement can be closely
related to the loss of pulmonary function as measured by
PFTs. The combination of multiple parenchymal lesions,
represented in our study by total HRCT score, seems more
responsible for the loss of pulmonary function than every
individual pathological alteration.
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